Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08UZL
|
|||
Former ID |
DNC001452
|
|||
Drug Name |
TMPyP4
|
|||
Synonyms |
TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Investigative | [1] | |
Company |
Geron Corp
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C44H38N8+4
|
|||
Canonical SMILES |
C[N+]1=CC=C(C=C1)C2=C3C=CC(=C(C4=NC(=C(C5=CC=C(N5)C(=C6C=CC2=N6)C7=CC=[N+](C=C7)C)C8=CC=[N+](C=C8)C)C=C4)C9=CC=[N+](C=C9)C)N3
|
|||
InChI |
1S/C44H37N8/c1-49-21-13-29(14-22-49)41-33-5-7-35(45-33)42(30-15-23-50(2)24-16-30)37-9-11-39(47-37)44(32-19-27-52(4)28-20-32)40-12-10-38(48-40)43(36-8-6-34(41)46-36)31-17-25-51(3)26-18-31/h5-28H,1-4H3,(H,45,46,47,48)/q+3/p+1
|
|||
InChIKey |
ABCGFHPGHXSVKI-UHFFFAOYSA-O
|
|||
CAS Number |
CAS 38673-65-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
602793, 866162, 6903208, 7889988, 14888385, 26697455, 26713701, 26715913, 26759637, 29223336, 50064752, 50071044, 57244597, 57322202, 75041861, 85286112, 103134351, 103255147, 104002923, 104305812, 117393983, 134340634, 135021834, 137023655, 137540646, 139738259, 139928079, 140013908, 142721654, 143123259, 143123269, 160855832, 162848634, 163687218, 226613199
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | Inhibitor | [1] |
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
Regulation of Telomerase | ||||
IL2 signaling events mediated by PI3K | ||||
Regulation of nuclear beta catenin signaling and target gene transcription | ||||
HIF-1-alpha transcription factor network | ||||
Reactome | Formation of the beta-catenin:TCF transactivating complex |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.